Molecular Biomarkers Predictive of Sertraline Treatment Response in Young Children With Autism Spectrum Disorder. by Alolaby, Reem Rafik et al.
UC Davis
UC Davis Previously Published Works
Title
Molecular Biomarkers Predictive of Sertraline Treatment Response in Young Children 
With Autism Spectrum Disorder.
Permalink
https://escholarship.org/uc/item/3n6774pz
Authors
Alolaby, Reem Rafik
Jiraanont, Poonnada
Durbin-Johnson, Blythe
et al.
Publication Date
2020
DOI
10.3389/fgene.2020.00308
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
fgene-11-00308 April 9, 2020 Time: 15:54 # 1
ORIGINAL RESEARCH
published: 15 April 2020
doi: 10.3389/fgene.2020.00308
Edited by:
Wanqing Liu,
Wayne State University, United States
Reviewed by:
Meenal Gupta,
The University of Utah, United States
Shengying Qin,
Shanghai Jiao Tong University, China
*Correspondence:
Flora Tassone
ftassone@ucdavis.edu
†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Pharmacogenetics
and Pharmacogenomics,
a section of the journal
Frontiers in Genetics
Received: 29 October 2019
Accepted: 16 March 2020
Published: 15 April 2020
Citation:
Alolaby RR, Jiraanont P,
Durbin-Johnson B, Jasoliya M,
Tang H-T, Hagerman R and Tassone F
(2020) Molecular Biomarkers
Predictive of Sertraline Treatment
Response in Young Children With
Autism Spectrum Disorder.
Front. Genet. 11:308.
doi: 10.3389/fgene.2020.00308
Molecular Biomarkers Predictive
of Sertraline Treatment Response
in Young Children With Autism
Spectrum Disorder
Reem Rafik Alolaby1†, Poonnada Jiraanont2†, Blythe Durbin-Johnson3, Mittal Jasoliya4,
Hiu-Tung Tang4, Randi Hagerman5,6 and Flora Tassone4,5*
1 College of Health Sciences, California Northstate University, Rancho Cordova, CA, United States, 2 Faculty of Medicine,
King Mongkut’s Institute of Technology Ladkrabang, Bangkok, Thailand, 3 Division of Biostatistics, School of Medicine,
University of California, Davis, Davis, CA, United States, 4 Department of Biochemistry and Molecular Medicine, School
of Medicine, University of California, Davis, Davis, CA, United States, 5 MIND Institute, University of California Davis Medical
Center, Davis, Davis, CA, United States, 6 Department of Pediatrics, School of Medicine, University of California, Davis,
Davis, CA, United States
Sertraline is one among several selective serotonin reuptake inhibitors (SSRIs) that
exhibited improvement of language development in Autism Spectrum Disorder (ASD);
however, the molecular mechanism has not been elucidated. A double blind,
randomized, 6-month, placebo-controlled, clinical trial of low-dose sertraline in children
ages (3–6 years) with ASD was conducted at the UC Davis MIND Institute. It aimed
at evaluating the efficacy and benefit with respect to early expressive language
development and global clinical improvement. This study aimed to identify molecular
biomarkers that might be key players in the serotonin pathway and might be predictive
of a clinical response to sertraline. Fifty eight subjects with the diagnosis of ASD were
randomized to sertraline or placebo. Eight subjects from the sertraline arm and five
from the placebo arm discontinued from the study. Furthermore, four subjects did
not have a successful blood draw. Hence, genotypes for 41 subjects (20 on placebo
and 21 on sertraline) were determined for several genes involved in the serotonin
pathway including the serotonin transporter-linked polymorphic region (5-HTTLPR), the
tryptophan hydroxylase 2 (TPH2), and the Brain-Derived Neurotrophic Factor (BDNF ).
In addition, plasma levels of BDNF, Matrix metallopeptidase 9 (MMP-9) and a selected
panel of cytokines were determined at baseline and post-treatment. Intent-to-treat
analysis revealed several primary significant correlations between molecular changes
and the Mullen Scales of Early Learning (MSEL) and Clinical Global Impression Scale –
Improvement (CGI-I) of treatment and control groups but they were not significant after
adjustment for multiple testing. Thus, sertraline showed no benefit for treatment of young
children with ASD in language development or changes in molecular markers in this
study. These results indicate that sertraline may not be beneficial for the treatment of
children with ASD; however, further investigation of larger groups as well as longer term
follow-up studies are warranted.
Keywords: Autism Spectrum Disorders, serotonin, sertraline, selective serotonin reuptake inhibitor, molecular
biomarkers
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INTRODUCTION
According to the American Psychiatric Association’s Diagnostic
and Statistical Manual of Mental Disorders, version-5,
Autism Spectrum Disorder (ASD) is a neurodevelopmental
disorder characterized by impairments in two domains: (1)
communication and social interaction and (2) restricted,
repetitive, and stereotyped patterns of behaviors and interests
(APA, 2013). According to Center for Disease Control
and Prevention, 1 in 59 children is diagnosed with ASD.
Approximately 30% of individuals with ASD also require
psychological and psychiatric treatments for behavioral problems
including hyperactivity, impulsivity, inattention, aggression,
property destruction, self-injury, mood disorders, psychosis, and
tic disorders (Lecavalier, 2006; Butler et al., 2012). Symptoms
of ASD usually begin in early childhood and are frequently
accompanied by intellectual disability (75%), dysmorphic
features and epilepsy (25%), and occasionally MRI and EEG
abnormalities (Miles and Hillman, 2000; Brooks-Kayal, 2010;
Chugani, 2012). However, since there are no definite biomarkers,
the diagnosis is based on a standardized clinical assessment and
relies basically on behaviors including speech delay and language
deficits (Lord et al., 2018).
Several neuroimaging and genetic studies indicate
dysregulation of serotonin in the pathogenesis of ASD.
Serotonin is a neurotransmitter synthesized in the central
nervous system (CNS) and plays a pivotal role in brain
development. Dysregulation in serotonin is associated with
aggression, anxiety, mood, impulsivity, sleep, ingestion behavior,
and reward systems (Cook and Leventhal, 1996; Chugani, 2002).
Perhaps the most intriguing 5HT-related finding in ASD is
hyperserotonemia, an increase of platelet 5-HT, which has been
consistently observed in about one third of subjects with ASD
(Anderson et al., 1990; Cook and Leventhal, 1996; Mulder,
2006; Hranilovic et al., 2007). In addition, reduction in uptake
of tryptophan (the precursor of 5-HT) and 5-HT synthesis,
decreased 5-HT2A receptor binding, and binding capacity of
5-HT transporter molecules (SERT, 5-HTT) have been detected
in autistic brain using positron emission tomography and
single-photon emission computed tomography (Chugani et al.,
1999; Chandana et al., 2005; Makkonen et al., 2008; Goldberg
et al., 2009; Oblak et al., 2013).
Evidence showed the global 5-HT synthesis in frontal,
temporal, and parietal cortex in children aged 2–5 years with ASD
was significantly attenuated compare to neurotypical children
which correlated with altered language development suggesting
a disruption of serotonergic system in ASD brains during early
childhood (Chugani et al., 1999). As mentioned earlier, the
serotonin transporter (5-HTT) involved in hyperserotonemia is
encoded by SLC6A4 gene, for which a causal link to ASD has
been reported (Marazziti et al., 2000; Wassink et al., 2007). The
most extensively studied polymorphism associated with ASD
is in the serotonin Transporter-linked polymorphic region (5-
HTTLPR) located within the promoter region of the gene and
presented with two alleles designated long (l) and short (s).
Both modulate the expression and function of the serotonin
transporter and they have been correlated with cerebral gray
matter volume, hippocampal volume and amygdala response in
ASD (Wassink et al., 2007), aggression and ADHD in males
(Cadoret et al., 2003).
In addition, case-control and family-based investigations
with molecular approaches unveiled serotonin-associated
candidate genes in ASD including tryptophan hydroxylase
2 (TPH2), Brain-Derived Neurotrophic Factor (BDNF) and
Matrix metallopeptidase 9 (MMP-9) (Noroozi et al., 2016; Meng
et al., 2017; Barrie et al., 2018). TPH2 is a gene located on
chromosome 12 encoding for a rate-limiting enzyme for brain
serotonin synthesis playing a role in ASD susceptibility associated
phenotypic impairments and repetitive behavior (Coon et al.,
2005; McKinney et al., 2005; Zafeiriou et al., 2009). However,
some studies have shown no significant correlation between
TPH2 variants and ASD (Ramoz et al., 2006; Sacco et al., 2007).
BDNF has long been the focus of attention for underlying
mechanisms leading to ASD. Several studies showed significant
correlations between elevated BDNF levels in serum or
blood and ASD (Miyazaki et al., 2004; Nishimura et al.,
2007; Correia et al., 2010; Ricci et al., 2013; Zhang et al.,
2014). BDNF has a trophic effect for dopaminergic neurons
both during brain development and maturity. It is involved
in regulating neuronal survival, morphology, differentiation,
synapse formation, and normal cognitive function. BDNF
is trophic for CNS serotonin as well (McAllister, 2001;
Anderson and Lombroso, 2002; Binder and Scharfman, 2004a,b,
Gunstad et al., 2008). A study in rodents has indicated
that BDNF and serotonin react to the same environmental
factors in reciprocal manner (Mattson et al., 2004). For
instance, heterozygous BDNF mice are extremely deprived of
serotonin clearance in the CA3 region of hippocampus due
to functional impairment of serotonin transporter rather than
total amount of serotonin transporter (Daws et al., 2007).
Notably, 5-HT and extracellular matrix (ECM) regulate learning
and memory formation through morphological changes of
dendritic spines during brain development (Udo et al., 2005;
Dityatev et al., 2010).
MMP-9, one of various ECM modifiers, serves a pivotal role
in long-term memory, synaptic plasticity, development of the
CNS during synaptogenesis, as well as in neuro-inflammation,
which are features consistently found in children with ASD
(Rosenberg, 2002; Yong, 2005; Ethell and Ethell, 2007; Huntley,
2012). Intriguingly, amniotic fluid samples derived from 331
ASD individuals exhibited increased levels of MMP-9 which
may imply the neuroplastic disruption during prenatal period
(Abdallah et al., 2012). Elevated MMP-9 activation can also
cause increased BDNF release and may contribute to the ASD
phenotype, including autistic-like behavior and macrocephaly
(Courchesne et al., 2003; Lainhart et al., 2006; Yoo et al.,
2016). Taken together, serotonin-associated genes including
TPH2, BDNF, and MMP-9 may be involved in the disruption
of the serotonergic system and ultimately play a role in the
pathology of ASD.
Selective serotonin reuptake inhibitors (SSRIs), which are
widely prescribed and can influence peripheral and CNS
5-HT levels may correct dysregulation and alleviate ASD
symptoms (Kolevzon et al., 2006). The Food and Drug
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Administration has approved several SSRIs including citalopram,
escitalopram, fluoxetine, fluvoxamine, and sertraline for treating
psychiatric symptoms in ASD (Nadeau et al., 2011). However,
a placebo-controlled study reporting the efficacy of sertraline
in ASD patients has not been carried out. Steingard et al.
(1997) reported the results of an open-label study of low
dosed sertraline (25–50 mg daily) in nine children with ASD
(6–12 years) and showed significant improvement in anxiety,
irritability, and inflexibility. Later, McDougle et al. (1998)
reported marked reduction of aggressive and repetitive behaviors
in adult ASD patients.
Thus, evidence suggests that sertraline could be useful in
young children with ASD since the serotonergic system is
disrupted in early development of ASD children. Based on these
findings, a 6-month randomized, placebo-controlled, double-
blind clinical trial of low-dose sertraline in children ages 39–
71 months old with ASD was conducted at the UC Davis
MIND Institute to evaluate the efficacy and benefit with
respect to early expressive and receptive language development
and global clinical improvement (Potter et al., 2019). In the
present study, we further investigated the participants to identify
molecular biomarkers predictive of efficacy and responsiveness
to sertraline treatment in ASD. Candidate genes were selected
specifically on the basis of their role in serotonin metabolism,
uptake and transport, including TPH-2, 5-HTTLPR, MMP-9,
and BDNF.
MATERIALS AND METHODS
Study Design
A 6-month randomized, placebo-controlled, double-blind
clinical trial of sertraline treatment was conducted at the UC
Davis MIND Institute. 179 subjects were screened for eligibility,
and a total of 58 were randomized; 32 subjects to sertraline and
26 to placebo. Thirteen subjects, eight from the sertraline arm
and five from the placebo arm, discontinued from the study.
Forty five ASD subjects aged 39–71 months completed the
sertraline clinical trial. However, for four subjects a blood sample
was not obtained. Thus, biological specimens were collected for
41 subjects including eight females and 33 males. All patients
were randomized and either received a placebo (n = 20) or
sertraline (n = 21). This was the first exposure to sertraline for all
the children. Sertraline was administered in liquid form in a dose
of 2.5 mg per day in patients ages 2–3 years and 5.0 mg per day
in those 4–6 years. The amount that was used at each 3 months
visit was measured to document compliance. More details are
described in Potter et al. (2019). Biological samples collected
at baseline and post-treatment were approved by the UC Davis
Institutional Review Board.
Clinical Measures
Clinical assessment of study participants involved primary
outcome measures: Mullen Scales of Early Learning (MSEL)
(Mullen, 1995) expressive language raw score, expressive
language standard score and Clinical Global Impression Scale-
Improvement (CGI-I). The CGI-I score is a follow-up measure
scored as follows: 1 = very much improved since the
initiation of treatment; 2 = much improved; 3 = minimally
improved; 4 = no change from baseline; 5 = minimally
worse; 6 = much worse; 7 = very much worse since
the initiation of treatment (Busner and Targum, 2007).
Additionally, the following secondary outcome measures were
used: MSEL subscales: fine motor, visual reception and receptive
language score. For each participant, all assessments were
completed both at baseline and at the 6-month follow
up visit.
Molecular Measures
Genomic DNA was isolated from 3 ml of peripheral blood
following standard procedure (Qiagen, Valencia, CA) and
used for genotype analysis. Plasma was collected using EDTA
containing blood collection tubes: blood was centrifugated for
10 min at 1000 × g within 2 h of blood collection. Plasma was
collected, aliquoted, and stored at−80◦C.
5-HTTLPR was performed using 100–200 ng genomic DNA
and 20 µM of the following specific primers, forward HTTP2A
(5′-TGA ATG CCA GCA CCT AAC CC-3′), reverse HTTP2A
(5′-TTC TGG TGC CAC CTA GAC GC-3′), following PCR
conditions as detailed in Tassone et al. (2011). BDNF (rs6265)
and TPH2 (rs4290270, rs7305115, rs11178997, and rs4570625)
genotypes were determined using TaqMan SNP Genotyping
Assay (Applied Biosystems) and the 7900HT Sequencer and
Sequence Detection System Software (Applied Biosystems, Inc.,
Foster City, CA).
Plasma samples were collected from purple top EDTA
containing collection tubes, to compare chemokines, MMP-9 and
BDNF levels before and after intervention. Furthermore, plasma
samples from nine typically developing male controls (Age range:
4–18 years old) were used to compare their BDNF and MMP-9
plasma levels to children with ASD, respectively.
To determine the MMP-9 plasma activity, the Human
MMP Magnetic Bead Panel 2 96-Well Plate Assay (Merck
Millipore, Billerica, MA) was used. Preparation of plasma
samples and reactions were performed according to the
manufacturer’s protocol.
BDNF plasma levels were measured using a Milliplex assay
(EMD-Millipore-Bellerica/MA). Samples were diluted 100-fold
with Assay Buffer. Overnight incubation was carried out for
17 h at 4◦C with shaking. Samples were measured within 1 h of
finishing protocol using Luminex bead reader.
Cytokine and Chemokine levels were measured using
Milliplex MAP Human Cytokine and Chemokine Magnetic Bead
Panel Immunoassay (EMD-Millipore-Bellerica/MA). It was a 10
plex kit which included beads specific for IL-1b, IL-2, IL-4, IL-5,
IL-6, IL-10, IL-12(p70), IL-13, IFNg, TNFa. Plasma samples were
prepared according to manufacturer’s protocol and the plates
were read on Bio-Plex 200 System (Bio-Rad).
Statistical Analysis
Mean subject age was compared between treatment groups
using a two-sample t-test, and the proportions of male and
female subjects were compared between treatment groups using
Fisher’s Exact Test.
Frontiers in Genetics | www.frontiersin.org 3 April 2020 | Volume 11 | Article 308
fgene-11-00308 April 9, 2020 Time: 15:54 # 4
Alolaby et al. Molecular Biomarkers of Sertraline in ASD
The association between MSEL receptive and expressive
language raw scores at baseline and molecular measures at
baseline was analyzed using linear regression. The association
between baseline CGI-S score and molecular measures
at baseline was analyzed using proportional odds logistic
regression (Agresti and Kateri, 2011). P-values were adjusted
for multiple testing across molecular measures using the
Benjamini-Hochberg false discovery rate controlling method
(Benjamini and Hochberg, 1995).
The association between BDNF expression at baseline and
BDNF genotype was analyzed using a one-way ANOVA model
and Tukey HSD pairwise comparisons.
The changes in treatment group subjects in MSEL receptive
language and expressive language scores were compared between
genotypes using one-way ANOVA models and Tukey pairwise
comparisons. CGI-I scores were compared between genotypes
using proportional odds logistic regression.
Changes from baseline in molecular measures were compared
between groups using one-way ANOVA models, with P-values
adjusted across molecular measures using the Benjamin-
Hochberg method.
The association between changes from baseline in MSEL
receptive language and expressive language and changes from
baseline in molecular measures were analyzed by group using
linear models with effects for the molecular measure, treatment
group, and their interaction. The association between CGI-
I and changes from baseline in molecular measures was
analyzed using proportional odds logistic regression models
with effects for the molecular measure, treatment group, and
their interaction.
Baseline expression of BDNF and MMP-9 was compared
between cases and controls using ANOVA models.
BDNF was log transformed prior to analysis for scaling
purposes and to more closely satisfy ANOVA model assumptions.
MMP-9 was log transformed in the analysis in which it was
used as a response (that comparing MMP-9 between cases and
controls) in order to more closely satisfy model assumptions.
Analyses were conducted using R, version 3.5.3 (R Core
Team, 2019) Proportional odds logistic regression models
were fitted using the R package ordinal, version 2019.2-9
(Christensen, 2019).
RESULTS
Study Subjects
Biological samples were collected at baseline for 45 subjects
(pre-treatment), among which 41 subjects had their follow up
visits (post treatment). Forty one biological samples were used
to compare the plasma levels of MMP-9, BDNF and selected
cytokines. Among the 41 subjects, 20 were on placebo and 21
were treated with sertraline. The mean age at baseline for the
placebo group was 51.9 months and that of the treatment group
was 50.6 months (Table 1).
Plasma samples derived from age and gender matched
control children were utilized for measuring BDNF and MMP-9
levels for comparison.
TABLE 1 | Subject Demographic Characteristics. Summary of age and gender by
treatment group.
Placebo Treatment All
subjects
P-value
Agea at Nc 20 21 41 0.71
baseline Mean (SD) 51.9 (10.5) 50.6 (11.4) 51.2 (10.9)
(months) Median
(range)
54.5 (31–71) 54 (32–69) 54 (31–71)
Genderb Female 4 (20%) 4 (19%) 8 (19.5%) 1
Male 16 (80%) 17 (81%) 33 (80.5%)
aAge was compared between groups using a two-sample t-test. bGender
was compared between groups using Fisher’s exact test. cN indicates the
number of subjects.
Molecular Measures
Linear regression analyses of MSEL receptive language raw score
at baseline by molecular measures at baseline showed that higher
expression of IL-5 at baseline is associated with a significantly
lower baseline MSEL receptive language raw score (P = 0.030),
however, this result was no longer significant after multiple
testing adjustment (adjusted P = 0.362).
An ANOVA model was used to compare BDNF expression
level between children with ASD and controls. The results show
that children with ASD had significantly higher BDNF expression
levels compared to typical age matched children (Figure 1A).
However, sertraline did not normalize the BDNF levels in those
treated with sertraline compared to the placebo group. Lower
MMP-9 expression levels were observed children with ASD than
controls (P = 0.026) (Figure 1B). No difference in BDNF and
MMP-9 expression were observed between the treatment and the
placebo group at baseline.
When comparing the changes in MSEL expressive language
raw score by TPH2 (rs11178997) (A/T), we observed that
subjects with the AT genotype had significantly higher MSEL
expression language raw scores than subjects with the TT
genotype (P = 0.031) (Table 2). Furthermore, after comparing
the changes in MSEL expressive language raw scores by TPH2
(rs4290270), it was shown that subjects with the AA genotype
had marginally significantly higher changes in MSEL expressive
language raw scores compared to subjects with the TT genotype
(0.049), with subjects with the AA genotype showing an increase
in score and subjects with the TT genotype showing a decrease in
score (Table 2).
ANOVA models were used to compare changes in molecular
measures between treatment groups. The results showed that
BDNF expression decreases significantly in both the treatment
(P = 0.001) and placebo (P = 0.011) groups (Figure 2). Although
in the treatment group, IL-5 (P = 0.035) and IL-10 decreased
significantly (P = 0.041), none of the changes were significant
after multiple testing adjustment. No significant associations or
changes between groups were observed for any of the other
molecular markers.
The results of linear models of change in MSEL receptive
language raw score by changes in molecular measures in each
group showed that there is a significant relationship between
the pre-post change in MSEL receptive language raw score and
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FIGURE 1 | Boxplots showing significantly higher plasma BDNF levels (A) and lower MMP-9 levels (B) in the ASD group compared to controls. The heavy line in
each box represents the median, the lower and upper box edges represent the 25th and 75th percentiles, respectively, and the lower and upper whiskers represent
the smallest and largest observations, respectively.
TABLE 2 | MSEL Expressive Language Raw Score – Change by TPH2
(rs11178997) (A/T) and TPH2 (rs4290270) (A/T) genotypes in the treatment group.
Genotypea Mean (95%
Confidence Interval)
P-valueb
TPH2 AT (nc = 3) 16.00 (4.90, 27.10) 0.008
(rs11178997) TT (nc = 12) 2.08 (−3.46, 7.63) 0.432
TPH2 AA (nc = 6) 12.0 (4.47, 19.53) 0.004
(rs4290270) AT (nc = 8) 0.5 (−6.02, 7.02) 0.872
TT (nc = 3) −4.0 (−14.65, 6.65) 0.434
Comparison Difference in means
(95% Confidence
Interval)
P-valueb
TPH2
(rs11178997)
AT – TT 13.9 (1.51, 26.3) 0.031
TPH2 AA – AT 11.5 (−0.6593, 23.7) 0.065
(rs4290270) AA – TT 16.0 (0.0797, 31.9) 0.049
AT – TT 4.5 (−10.7425, 19.7) 0.725
aGenotypes with fewer than three subjects with non-missing data were excluded.
bP-values are adjusted for multiple pairwise comparisons using the Tukey HSD
method. cN indicates the number of subjects.
change in several cytokines which were not statistically significant
following adjustment for multiple testing.
DISCUSSION
Selective serotonin reuptake inhibitors, including sertraline,
inhibit the serotonin transporter which normally reuptakes
serotonin into presynaptic serotonergic neurons, subsequently,
increasing extracellular levels of serotonin (Blakely et al., 1991).
FIGURE 2 | The graphs show a significant improvement for baseline to after
treatment in the BDNF plasma level in both the sertraline and placebo groups.
A line plot of log10 BDNF plasma levels by time point. Colored lines represent
individual subjects and the heavy black lines show the group means.
Sertraline has been approved to treat OCD in patients with ASD,
based on the shared core symptoms of repetitive thoughts and
behaviors in addition to the dysfunction of serotonergic system
(Bastani et al., 1991; McDougle et al., 2000).
In this study we investigated the predictive efficacy of
molecular biomarkers of sertraline, including BDNF, MMP-9,
TPH-2 and cytokines to determine whether sertraline normalizes
the expression of any of these genes in young children with ASD.
BDNF is important for the regulation of neurodevelopment
and neuroplasticity thus contributing to normal learning process
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and memory. Several studies demonstrated that BDNF levels in
young children with ASD are higher than aged-match typical
neurodevelopmental adults (Perry et al., 2001; Miyazaki et al.,
2004). Excess of BDNF and other neurotrophins may affect
tissue volume (Conover et al., 1995; Wassink et al., 1999). Taken
together, elevated BDNF at early life may play an etiological role
in ASD. This might be represented by the brain overgrowth
as observed in many ASD children (Courchesne et al., 2001;
Wassink et al., 2007; Lainhart and Lange, 2011; Hazlett et al.,
2012; Armeanu et al., 2017). Consistently with previous studies
we found that BDNF levels were significantly higher in ASD
compared to controls (Miyazaki et al., 2004; Connolly et al.,
2006; Nelson et al., 2006; Nishimura et al., 2007; Correia et al.,
2010; Ricci et al., 2013; Zhang et al., 2014). However, these
increased levels of BDNF were not normalized by sertraline.
Specifically, our results show that the elevated BDNF levels in
ASD are significantly larger than controls and sertraline can
partially reduce the BDNF levels both in the treatment and
placebo groups although there was no significantly difference
after correction. As peripheral expression levels of BDNF in rats
are associated with the level in CNS, we might imply that the
concentration of peripheral BDNF can reflect the expression level
in ASD brain as well (Karege et al., 2002; Fernandes et al., 2015).
Accordingly, peripheral BDNF might be a potential biomarker for
ASD (Zheng et al., 2016).
Plasma MMP-9 expression levels in ASD were significantly
lower than controls which is contrary to the elevated MMP-
9 levels in amniotic fluid samples from 331 ASD cases
suggesting fluctuation of MMP-9 during early development in
ASD (Abdallah et al., 2012). Despite different MMP-9 expression
levels, sertraline had no effect on MMP-9. MMP-9 plays a pivotal
role in neuronal survival, CNS development, synaptic plasticity,
and neuroinflammation through triggering several neurotrophic
factors including BDNF (Gijbels et al., 1994; Rosenberg, 2002;
Ethell and Ethell, 2007; Fujioka et al., 2012). Hence, it is plausible
that MMP-9 might contribute to the etiopathology of ASD
as well. On the other hands, MMP-9 can also mediate the
inflammatory response through promoting proteolysis either by
stimulating or suppressing inflammatory cytokines involved in
ASD pathology (Yoo et al., 2002; Parks et al., 2004; Deverman
and Patterson, 2009). However, in our study, no significant
differences were observed.
Extensive evidence has suggested the role of pro-inflammatory
and anti-inflammatory cytokines involving the severity of
problematic behaviors and developmental and adaptive
malfunctions as seen in ASD (Ashwood et al., 2011a,b, Napolioni
et al., 2013). However, heterogeneity of immune function
findings in ASD may imply that there is no definite type of
inflammatory response responsible for the etiology of ASD
(Mead and Ashwood, 2015).
The human TPH2 is exclusively expressed in the brain,
particularly in the serotonergic neurons of the dorsal and
median raphe nuclei which is the primary source of serotonin
(Walther et al., 2003; Bach-Mizrachi et al., 2006; Zill et al., 2007).
Accumulating evidence has proposed that several functional
polymorphisms of TPH2 gene are associated with psychiatric
disorders including major depressive disorder (MDD), attention
deficit hyperactivity disorder (ADHD), schizophrenia, and
bipolar disorder (De Luca et al., 2004; De Luca et al., 2005;
Sheehan et al., 2005; Cichon et al., 2007; Haghighi et al., 2008;
Gao et al., 2012).
The functional consequences of single nucleotide
polymorphisms (SNPs) are not clear but could potentially
modify the expression and the function of the TPH2 gene.
Candidate TPH2 variants including the ones in our study
have long been well replicated in case of MDD (Mandelli
et al., 2012; Van der Auwera et al., 2014; Han et al., 2017).
Further, associations between TPH2 polymorphisms and ASD
susceptibility particularly repetitive and stereotyped behaviors
suggesting that they might affect the ASD phenotypes and
augment ASD susceptibility have been reported (Coon et al.,
2005; Yang et al., 2012; Barrie et al., 2018). However, in our
treatment group the rs11178997 with AT genotype demonstrated
significantly higher expression language raw scores than the TT
genotype. Furthermore, variant rs4290270 with AA genotype
showed slightly increased scores compared to TT genotype. Our
findings suggest that sertraline might play a moderate role in
expressive language in ASD depending on the TPH2 genotype.
CONCLUSION
In conclusion, sertraline had no distinct effect on young children
with ASD compared to placebo and on several biomarkers
including in this trial albeit their potential from ample previous
studies. Future investigations should be of longer duration and
should include more ASD subjects, which is a limitation of this
study, with less heterogeneity to gain more insights on how to
improve the quality of life of children with ASD.
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